WeischerMJuulKZachoJ. Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis. 2010;208(2):480–3.
5.
ThomasDPMertonREWoodRDHockleyDJ. The relationship between vessel wall injury and venous thrombosis: an experimental study. Br J Haematol. 1985;59(3):449–57.
CotranRSPoberJS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol. 1990;1(3):225–35.
8.
van HinsberghVW. Endothelium—role in regulation of coagulation and inflammation. Semin Immunopathol. 2012;34(1):93–106.
9.
PoredosP. Endothelial dysfunction and cardiovascular disease. Pathophysiol Haemost Thromb. 2002;32(5-6):274–7.
10.
MooreKLEsmonCTEsmonNL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood. 1989;73(1):159–65.
11.
PearsonJD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12(3):329–41.
12.
PepperMSFerraraNOrciLMontesanoR. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181(2):902–6.
13.
YauJWTeohHVermaS. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15:130.
14.
BorissoffJISpronkHMten CateH. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364(18):1746–60.
15.
GoriTDragoniSLisiM. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol. 2008;51(20):1953–8.
16.
SpiekerLELüscherTFNollG. ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans. J Cardiovasc Pharmacol. 2003;42(3):315–8.
17.
BellienJJoannidesRIacobMArnaudPThuillezC. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol. 2006;290(4):H1347–52.
18.
KuvinJTPatelARSlineyKA. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003;146(1):168–74.
19.
PoredosPJezovnikMK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb. 2013;20(1):1–8.
20.
SchindlerCGrossmannMDobrevDFranckeKRavensUKirchW. Reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin F2 alpha using the dorsal hand vein compliance method. J Clin Pharmacol. 2003;43(3):228–36.
21.
AelligWH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol. 1981;11(3):237–43.
22.
RutlenDLWackersFJZaretBL. Radionuclide assessment of peripheral intravascular capacity: a technique to measure intravascular volume changes in the capacitance circulation in man. Circulation. 1981;64(1):146–52.
23.
SchmittMBlackmanDJMiddletonGWCockcroftJRFrenneauxMP. Assessment of venous capacitance. Radionuclide plethysmography: methodology and research applications. Br J Clin Pharmacol. 2002;54(6):565–76.
24.
AndersonTJGerhardMDMeredithIT. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75(6):71B–4B.
25.
MigliacciRBecattiniCPesaventoR. Endothelial dysfunction in patients with spontaneous venous thromboembolism. Haematologica. 2007;92(6):812–8.
26.
JezovnikMKPoredosPStalcM. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis. J Atheroscler Thromb. 2010;17(11):1190–8.
27.
JezovnikMKFareedJPoredosP. Patients with a history of idiopathic deep venous thrombosis have long-term increased levels of inflammatory markers and markers of endothelial damage. Clin Appl Thromb Hemost. 2017;23(2):124–31.
28.
GaizAMosawySColsonNSinghI. Thrombotic and cardiovascular risks in type two diabetes; role of platelet hyperactivity. Biomed Pharmacother. 2017;94:679–86.
29.
PomeroFDi MinnoMNFenoglioLGianniMAgenoWDentaliF. Is diabetes a hypercoagulable state? A critical appraisal. Acta Diabetol. 2015;52(6):1007–16.
30.
LinnemannBZgourasDSchindewolfMSchwonbergJJarosch-PreuscheMLindhoff-LastE. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis. 2008;19(2):159–65.
31.
ZizekBPoredosPVidecnikV. Endothelial dysfunction in hypertensive patients and in normotensive offspring of subjects with essential hypertension. Heart. 2001;85(2):215–7.
32.
BelattarFZDellucALe GalG. Antihypertensive drugs and risk of venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2010;24(2):255–9.
33.
KishiTHirookaYKonnoSSunagawaK. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens. 2012;30(8):1646–55.
34.
Di FrancescomarinoSSciartilliADi ValerioVDi BaldassarreAGallinaS. The effect of physical exercise on endothelial function. Sports Med. 2009;39(10):797–812.
35.
LakoskiSGSavagePDBerkmanAM. The safety and efficacy of early-initiation exercise training after acute venous thromboembolism: a randomized clinical trial. J Thromb Haemost. 2015;13(7):1238–44.
36.
TangphaoOChalonSMorenoHJAbioseAKBlaschkeTFHoffmanBB. Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther. 1999;66(3):232–8.
37.
BaerHJGlynnRJHuFB. Risk factors for mortality in the nurses’ health study: a competing risks analysis. Am J Epidemiol. 2011;173(3):319–29.
38.
PoredošP. Interrelationship between venous and arterial thrombosis. Int Angiol. 2017;36(4):295–8.
39.
FranchiniMMannucciPM. Association between venous and arterial thrombosis: clinical implications. Eur J Intern Med. 2012;23(4):333–7.
40.
GradyDWengerNKHerringtonD. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med. 2000;132(9):689–96.
41.
JezovnikMKPoredosPLusaL. Idiopathic venous thrombosis is associated with preclinical atherosclerosis. J Atheroscler Thromb. 2010;17(3):304–11.
42.
PoredosPJezovnikMK. Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost. 2011;37(8):897–902.
43.
VlachopoulosCXaplanterisPAboyansV. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) society. Atherosclerosis. 2015;241(2):507–32.
